Get the Stockscreener App
2.32
0.00%
0.00
After Hours:
2.31
-0.010
-0.43%
Editas Medicine Inc stock is traded at $2.32, with a volume of 1.70M.
It is up +0.00% in the last 24 hours and up +6.42% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary ene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
See More
Previous Close:
$2.32
Open:
$2.28
24h Volume:
1.70M
Relative Volume:
0.96
Market Cap:
$227.06M
Revenue:
$40.52M
Net Income/Loss:
$-160.06M
P/E Ratio:
-1.2318
EPS:
-1.8834
Net Cash Flow:
$-165.85M
1W Performance:
-1.28%
1M Performance:
+6.42%
6M Performance:
-28.40%
1Y Performance:
+82.68%
1-Day Range:
$2.24
$2.475
1-Week Range:
$2.23
$2.49
52-Week Range:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.32 | 227.06M | 40.52M | -160.06M | -165.85M | -1.8834 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | H.C. Wainwright | Buy |
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
EDITAS MEDICINE Operating Margin %: -56.65% | Fairly Valued - GuruFocus
MACD Signal: Can Editas Medicine Inc maintain sales growthEarnings Summary Report & Community Consensus Stock Picks - baoquankhu1.vn
How correlated is Editas Medicine Inc to the S P5002026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Q2 EPS Estimates for Editas Medicine Decreased by Analyst - MarketBeat
Zacks Research Weighs in on Editas Medicine FY2028 Earnings - MarketBeat
If You Invested $1,000 in Editas Medicine Inc (EDIT) - Stock Titan
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates - MSN
Editas Medicine, Inc. Trade Ideas — LS:A2AC4K - TradingView
RSI Check: Can Editas Medicine Inc outperform in the next rally2026 EndofMonth & High Accuracy Investment Signals - baoquankhu1.vn
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT) - The Globe and Mail
Institution Moves: Can Editas Medicine Inc disrupt its industry2026 News Drivers & Technical Pattern Based Buy Signals - baoquankhu1.vn
Editas Medicine (EDIT) Stock: 5-Year Valuation Drop & Recent Pipeline ChallengesNews and Statistics - IndexBox
Is Editas Medicine Going to $0? - The Globe and Mail
Can Editas Medicine Inc grow without external funding2026 Macro Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Ascend Wellness Holdings LLC (OtherAAWH) - The Globe and Mail
Is Editas Medicine Headed Toward Zero? - Bitget
Editas Medicine (EDIT) grants 292,856 stock options to chief scientific officer - Stock Titan
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401 - MarketBeat
Editas Medicine at Barclays Conference: Strategic Focus on CRISPR Innovation - Investing.com Canada
Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects - TipRanks
Editas Medicine (EDIT) Receives Upgrade to 'Buy' from Jones Trad - GuruFocus
Editas Medicine (NASDAQ:EDIT) Upgraded at JonesTrading - MarketBeat
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - The Globe and Mail
Jones Trading upgrades Editas Medicine stock rating on gene therapy progress - Investing.com Canada
Editas Medicine 2025 Annual Report: CRISPR Gene Editing Pipeline, EDIT-401 Program, Intellectual Property, and Industry Competition - Minichart
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates - Bitget
Editas: Q4 Earnings Snapshot - theheraldreview.com
Cowen Maintains Buy on EDIT Editas Medicine, Inc. March 2026 - Meyka
Baird reiterates Editas Medicine stock rating on pipeline progress By Investing.com - Investing.com Canada
Editas Medicine 10-K: $40.5M revenue, $(1.80) EPS - TradingView
Editas Medicine (NASDAQ: EDIT) pivots to in vivo CRISPR and monetizes IP - Stock Titan
Editas Medicine (EDIT): Today's Analyst Rating Insights | EDIT S - GuruFocus
Editas Medicine (NASDAQ:EDIT) Receives "Buy" Rating from Chardan Capital - MarketBeat
TD Cowen reiterates Editas Medicine stock Buy rating on pipeline progress - Investing.com Canada
BREAKING: EDIT Reports Narrower Loss for Q4 EPS, vs. $0.21 per share estimated - AlphaStreet
Editas Medicine earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Editas: Fourth Quarter Financial Overview - Bitget
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Editas Medicine Q4 2025 Financial Report: Loss of $5.6M, Revenue $24.7MNews and Statistics - IndexBox
Editas Medicine (EDIT) Reports Fourth Quarter Financials and Adv - GuruFocus
Editas Medicine posts fourth quarter and full year 2025 financial results - Traders Union
Editas Reports Q4 Earnings Beat - National Today
Editas Medicine stock rises 2% after Q4 earnings and revenue beats - Investing.com
Editas Medicine Q4 Earnings Beat Expectations - Intellectia AI
Editas Medicine (NASDAQ:EDIT) Announces Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Editas Medicine posts smaller‑than‑expected Q4 net loss on lower R&D spend - TradingView
Editas Medicine SVP Parison sells $957 in stock By Investing.com - Investing.com Canada
Editas Medicine SVP Parison sells $957 in stock - Investing.com
Editas Medicine EVP Burkly sells $1.5k in stock - Investing.com UK
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,394 Shares - MarketBeat
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):